Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
3
Expiration
Dec 4, 2026
DTE
21d
Moneyness
OTM
Intrinsic
$0.00
IBRX 3 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | — | — | 0 | 0 |
| Nov 20, 2026 | 7d | $0.03 | +0.00% | 1 | 1 |
| Nov 27, 2026 | 14d | $0.04 | +0.00% | 1 | 1 |
| Dec 4, 2026 | 21d | — | — | 0 | 0 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 18, 2026 | 35d | $0.05 | +0.00% | 100 | 100 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $0.05 | +0.00% | 1 | 2,647 |
| Mar 19, 2027 | 126d | $0.05 | -88.89% | 1 | 3 |
| Apr 16, 2027 | 154d | $0.33 | +65.00% | 1 | 3 |
| May 21, 2027 | 189d | — | — | 0 | 0 |
| Aug 20, 2027 | 280d | — | — | 0 | 0 |
| Nov 19, 2027 | 371d | — | — | 0 | 0 |
| Jan 21, 2028 | 434d | $0.35 | +0.00% | 25 | 194 |
| Mar 17, 2028 | 490d | $1.08 | +52.11% | 4 | 14 |
| Jan 19, 2029 | 798d | $0.64 | +42.22% | 1 | 11 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.